$1.75 Billion is the total value of Camber Capital Management LP's 30 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
GSK | GLAXOSMITHKLINE PLCsponsored adr | $122,370,000 | +7.7% | 3,000,000 | 0.0% | 7.00% | +3.1% | |
NKTR | NEKTAR THERAPEUTICS | $69,480,000 | +29.7% | 3,000,000 | 0.0% | 3.98% | +24.3% | |
COLL | COLLEGIUM PHARMACEUTICAL INC | $35,000,000 | +7.2% | 2,000,000 | 0.0% | 2.00% | +2.7% | |
AMAG | AMAG PHARMACEUTICALS INC | $33,584,000 | +23.8% | 4,390,000 | 0.0% | 1.92% | +18.6% | |
AVRO | AVROBIO INC | $23,558,000 | +12.1% | 1,350,000 | 0.0% | 1.35% | +7.5% | |
STRO | SUTRO BIOPHARMA INC | $4,656,000 | -23.9% | 600,000 | 0.0% | 0.27% | -27.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
MYLAN NV | 21 | Q3 2020 | 10.1% |
AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
Solid Biosciences Inc. | December 12, 2022 | ? | ? |
AVROBIO, Inc. | February 14, 2022 | ? | ? |
COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
Change Healthcare Inc. | February 16, 2021 | ? | ? |
GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
13F-HR | 2023-11-14 |
SC 13G | 2023-10-30 |
13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.